Back
Cardiotoxic transplacental effect of idarubicin administered during the second trimester of pregnancy.
Journal article

Cardiotoxic transplacental effect of idarubicin administered during the second trimester of pregnancy.

  • Achtari C Service de GynĂ©cologie et Obstetrique, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
  • Hohlfeld P
  • 2000-08-15
Published in:
  • American journal of obstetrics and gynecology. - 2000
Adult
Antibiotics, Antineoplastic
Female
Heart
Humans
Idarubicin
Leukemia-Lymphoma, Adult T-Cell
Placenta
Pregnancy
Pregnancy Trimester, Second
English Polychemotherapy including idarubicin was administered during the second trimester to treat acute lymphoblastic leukemia. The infant delivered at 28 weeks' gestation had acute cardiac failure attributed to the cardiotoxic effect of idarubicin. Cardiotoxicity may be caused by idarubicin's biophysical properties that facilitate its transplacental passage. Idarubicin should be used with extreme caution during pregnancy.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://sonar.ch/global/documents/93526
Statistics
Document views: 26 File downloads: